Correction: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol [Syst Rev. 4, (2015) (143)] DOI: 10.1186/s13643-015-0134-z.;Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol for a systematic review

Systematic Reviews

Volumn 4, Issue 1, 2015, Pages

  Mayo Wilson, Evan ^a   Hutfless, Susan ^a,b   Li, Tianjing ^a   Gresham, Gillian ^a   Fusco, Nicole ^a   Ehmsen, Jeffrey ^b   Heyward, James ^a   Vedula, Swaroop ^c   Lock, Diana ^a   Haythornthwaite, Jennifer ^b   Payne, Jennifer L ^b   Cowley, Theresa ^d   Tolbert, Elizabeth ^e   Rosman, Lori ^b   Twose, Claire ^b   Stuart, Elizabeth A ^a   Hong, Hwanhee ^a   Doshi, Peter ^f   Suarez Cuervo, Catalina ^a   Singh, Sonal ^b   Dickersin, Kay ^a   more..

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Johns Hopkins University   (United States)

^d TMJ Association Ltd   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Bipolar disorder; Depression; Gabapentin; Guidance; Meta analysis; Pain; Publication bias; Quetiapine; Reporting bias; Systematic reviews

Indexed keywords

GABAPENTIN; QUETIAPINE; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DEPRESSION; CLINICAL TRIAL (TOPIC); DATA PROCESSING; HUMAN; INFORMATION RETRIEVAL; METHODOLOGY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; BIPOLAR DISORDER; LITERATURE; META ANALYSIS (TOPIC); NEURALGIA; SELECTION BIAS; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA;

AMINES; ANALGESICS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CYCLOHEXANECARBOXYLIC ACIDS; DATA INTERPRETATION, STATISTICAL; GAMMA-AMINOBUTYRIC ACID; HUMANS; META-ANALYSIS AS TOPIC; NEURALGIA; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT-CENTERED CARE; QUETIAPINE FUMARATE; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; SELECTION BIAS;

EID: 84945945676     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/s13643-018-0711-z     Document Type: Erratum

References (78)

1. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev. 2007(2):MR000005. doi: 10.1002/14651858.MR000005.pub3.
2. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):1-193. doi: 10.3310/hta14080. iii, ix-xi.
3. Goodman S, Dickersin K. Metabias: a challenge for comparative effectiveness research. Ann Intern Med. 2011;155(1):61-2. doi: 10.7326/0003-4819-155-1-201107050-00010.
4. Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. PLoS Med. 2013;10(1):e1001378. doi: 10.1371/journal.pmed.1001378.
5. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gotzsche PC, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257-66. doi: 10.1016/S0140-6736(13)62296-5.
6. Lefebvre C, Glanville J, Wieland LS, Coles B, Weightman AL. Methodological developments in searching for studies for systematic reviews: past, present and future? Syst Rev. 2013;2:78. doi: 10.1186/2046-4053-2-78.
7. Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess. 2003;7(1):1-76.
8. Scherer RW, Huynh L, Ervin AM, Taylor J, Dickersin K. ClinicalTrials.gov registration can supplement information in abstracts for systematic reviews: a comparison study. BMC Med Res Methodol. 2013;13:79. doi: 10.1186/1471-2288-13-79.
9. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60. doi: 10.1056/NEJMsa065779.
10. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965. doi: 10.1002/14651858.CD008965.pub4.
11. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158(12):890-902. doi: 10.7326/0003-4819-158-12-201306180-00006.
12. Simmonds MC, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med. 2013;158(12):877-89. doi: 10.7326/0003-4819-158-12-201306180-00005.
13. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993;341(8842):418-22.
14. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221. doi: 10.1136/bmj.c221.
15. Rodgers MA, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Simmonds MC, et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ. 2013;346:f3981. doi: 10.1136/bmj.f3981.
16. Institute of Medicine. Finding what works in health care: standards for systematic reviews. Washington, DC: The National Academies Press; 2011.
17. Gabriel SE, Normand SL. Getting the methods right--the foundation of patient-centered outcomes research. N Engl J Med. 2012;367(9):787-90. doi: 10.1056/NEJMp1207437.
18. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361(20):1963-71. doi: 10.1056/NEJMsa0906126.
19. Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med. 2012;9(3):e1001189. doi: 10.1371/journal.pmed.1001189.
20. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31(1):140-9.
21. Li T, Yu T, Hawkins BS, Dickersin K. Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis. PLoS One. 2015;10(8):e0133023. doi: 10.1371/journal.pone.0133023.
22. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337-45.
23. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;4:CD007938. doi: 10.1002/14651858.CD007938.pub3.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
25. Glanville J, Duffy S, McCool R, Varley D. Searching ClinicalTrials.gov and the International Clinical Trials Registry Platform to inform systematic reviews: what are the optimal search approaches? J Med Lib Assoc. 2014;102(3):177-83.
26. Turner EH. How to access and process FDA drug approval packages for use in research. BMJ. 2013;347:f5992. doi: 10.1136/bmj.f5992.
27. Saldanha IJ, Dickersin K, Wang X, Li T. Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability. 2014.
28. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011;364(9):852-60. doi: 10.1056/NEJMsa1012065.
29. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007;7:32. doi: 10.1186/1471-2288-7-32.
30. FDA. COSTART: coding symbols for thesaurus of adverse reaction terms. Fourth Edition: Office of Management and Operations 1993.
31. ICH. Introductory Guide MedDRA Version 17.0: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 2014.
32. Schroll JB, Maund E, Gotzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012;7(7):e41174. doi: 10.1371/journal.pone.0041174.
33. Software OCR. ABBYY FineReader version 12. 2013.
34. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
35. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355-60. doi: 10.1056/NEJMsr1203730.
36. Mavridis D, Chaimani A, Efthimiou O, Leucht S, Salanti G. Addressing missing outcome data in meta-analysis. Evid Based Ment Health. 2014;17(3):85-9. doi: 10.1136/eb-2014-101900.
37. Mavridis D, White IR, Higgins JP, Cipriani A, Salanti G. Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Stat Med. 2014;34(5):721-41. doi: 10.1002/sim.6365.
38. Little RJA. Pattern-mixture models for multivariate incomplete data. J Am Stat Assoc. 1993;88:125-34.
39. White IR, Welton NJ, Wood AM, Ades AE, Higgins JP. Allowing for uncertainty due to missing data in meta-analysis-part 2: hierarchical models. Stat Med. 2008;27(5):728-45. doi: 10.1002/sim.3007.
40. Li T, Hutfless S, Scharfstein D, Daniels M, Hogan J, Little R, et al. Standards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus. J Clin Epidemiol. 2014;67(1):15-32.
41. PCORI. The PCORI Methodology Report. Appendix A: methodology standards. 2013.
42. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. Hoboken: Wiley; 2002.
43. StataCorp. Stata: Release 13. College Station, TX: StataCorp LP; 2013.
44. Horton NJ, Lipsitz SR. Multiple imputation in practice: comparison of software packages for regression models with missing variables. The American Statistician, American Statistical Association. 2001;55:244-54.
45. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci. 2007;8:206-13.
46. Moons KG, Donders RA, Stijnen T, Harrell Jr FE. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 2006;59(10):1092-101. doi: 10.1016/j.jclinepi.2006.01.009.
47. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi: 10.1136/bmj.b2393.
48. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377-99. doi: 10.1002/sim.4067.
49. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
50. Riley RD, Simmonds MC, Look MP. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. J Clin Epidemiol. 2007;60(5):431-9. doi: 10.1016/j.jclinepi.2006.09.009.
51. Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Thijs L, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate dat. Stat Med. 2008;27(11):1870-93.
52. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med. 1995;14(19):2057-79.
53. Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Stat Med. 2001;20(15):2219-41. doi: 10.1002/sim.918.
54. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med. 2000;19(24):3417-32.
55. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
56. Thompson SG, Higgins JP. Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? Lancet. 2005;365(9456):341-6. doi: 10.1016/S0140-6736(05)17790-3.
57. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton 3rd LJ. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009;10(3):586-93. doi: 10.1111/j.1526-4637.2009.00588.x.
58. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790-5.
59. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-27. doi: 10.1001/archpsyc.62.6.617.
60. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-51. doi: 10.1001/archgenpsychiatry.2011.12.
61. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21-35.
62. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry. 2004;65(11):1499-504.
63. Hirschfeld RM, Vornik LA. Recognition and diagnosis of bipolar disorder. J Clin Psychiatry. 2004;65 Suppl 15:5-9.
64. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-9.
65. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-7.
66. Ilgen MA, Bohnert AS, Ignacio RV, McCarthy JF, Valenstein MM, Kim HM, et al. Psychiatric diagnoses and risk of suicide in veterans. Arch Gen Psychiatry. 2010;67(11):1152-8. doi: 10.1001/archgenpsychiatry.2010.129.
67. Holma KM, Haukka J, Suominen K, Valtonen HM, Mantere O, Melartin TK et al. Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder. Bipolar Disorders. 2014:n/a-n/a. doi: 10.1111/bdi.12195.
68. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306-15. doi: 10.1016/S0140-6736(11)60873-8.
69. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303-12. doi: 10.1038/sj.npp.1301646.
70. Sanford M, Keating G. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012;26(5):435-60.
71. Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzalez-Pinto A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011;129(1-3):14-26. doi: 10.1016/j.jad.2010.05.018.
72. NICE. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: National Institute for Health and Care Excellence; 2014.
73. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93.
74. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-35. doi: 10.1056/NEJMoa0806994.
75. Hawley CJ, Finneberg N, Roberts AG, Baldwin D, Sahadevan A, Sharman V. The use of the Simpson Angus Scale for the assessment of movement disorder: a training guide. Int J Psych Clin Pract. 2003;7:249-57.
76. Rautaharju PM, Surawicz B. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV. Circulation. 2009;119:e241-e50.
77. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35.
78. Lukasiewicz M, Gerard S, Besnard A, Falissard B, Perrin E, Sapin H, et al. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res. 2013;22(1):46-58. doi: 10.1002/mpr.1379.